Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.

Flora ZagouriEfstathios KastritisAthanasios ZomasEvangelos TerposEirini KatodritouArgiris SymeonidisSosana DelimpasiAnastasia PouliTheodoros P VassilakopoulosEurydiki MichalisStavroula GiannouliZafiris KartasisAnna ChristoforidouKiriaki KokoviadouEleftheria HatzimichaelDimitra GikaCatherine MegalakakiMaria PapaioannouMarie-Christine KyrtsonisKostas KonstantopoulosMeletios A Dimopoulosnull null

Published in: European journal of haematology (2017)

Hypercalcemia remains a poor prognostic feature in the era of novel agents despite the improvement in the outcomes of patients who present with elevated calcium.

Keyphrases

prognostic factors
newly diagnosed
multiple myeloma
end stage renal disease
machine learning
peritoneal dialysis
emergency department
deep learning
type diabetes
metabolic syndrome
skeletal muscle
drug induced